LENZ THERAPEUTICS, INC. (LENZ) Operating Margin
- Operating margin · 12 months: Value -631.70%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -631.70% | Operating income / revenue. Period ending 2026-06-30. $-135.66M ÷ $21.48M × 100 ≈ -631.70% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -135.66M USD | Operating Income (Loss) |
| Revenue | 21.48M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.77M USD | Cost of Goods and Services Sold |
| Research and development | 3.79M USD | Research and Development Expense |
| Selling, general and administration | 151.57M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-135.66M | $21.48M | $1.77M | $3.79M | $151.57M | -631.70% |
| 2026-03-31 | $-118.34M | $20.99M | $1.49M | $12.85M | $124.98M | -563.83% |
| 2025-12-31 | $-91.14M | $19.09M | $418.00K | $18.67M | $91.14M | -477.46% |
| 2025-09-30 | $-67.90M | (m) | (m) | $24.54M | $60.86M | (m) |
| 2025-06-30 | $-61.96M | (m) | (m) | $27.20M | $39.76M | (m) |
| 2025-03-31 | $-59.45M | (m) | (m) | $25.08M | $34.37M | (m) |
| 2024-12-31 | $-58.61M | (m) | (m) | $29.80M | $28.81M | (m) |
| 2024-09-30 | $-131.14M | (m) | (m) | $16.10M | (m) | (m) |
| 2024-06-30 | $-138.06M | (m) | (m) | $26.66M | (m) | (m) |
| 2024-03-31 | $-138.66M | (m) | (m) | $32.35M | (m) | (m) |
| 2023-12-31 | $-135.19M | (m) | (m) | $32.14M | (m) | (m) |
| 2023-09-30 | $-136.39M | (m) | (m) | $50.60M | (m) | (m) |
| 2023-06-30 | $-137.51M | (m) | (m) | $66.52M | (m) | (m) |
| 2023-03-31 | $-106.13M | (m) | (m) | $70.78M | (m) | (m) |
| 2022-12-31 | $-105.64M | (m) | (m) | $72.79M | (m) | (m) |
| 2022-09-30 | $-97.83M | (m) | (m) | $65.53M | (m) | (m) |
| 2022-06-30 | $-86.28M | (m) | (m) | $55.91M | (m) | (m) |
| 2022-03-31 | $-77.03M | (m) | (m) | $50.80M | (m) | (m) |
| 2021-12-31 | $-60.44M | (m) | (m) | $37.93M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-13.50M | (m) | (m) | $9.12M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |